

# Index

- A**
- AAV. *See* Adeno-associated virus (AAV)
- Abatacept, 397, 398
- Absorption process, protein drugs  
  enteral administration, 102  
  parenteral administration, 102–104
- Acellular pertussis vaccines, 448
- ACER. *See* Average cost-effectiveness ratio (ACER)
- Acute myelogenous leukemia (AML), 90, 153, 341, 342, 369
- ADA formation. *See* Anti-drug antibodies (ADA) formation
- Adalimumab  
  CDAI, 405  
  clinical response and remission, 405  
  description, 394  
  efficacy and safety, 398–399  
  pediatric patients, 399
- Adaptive immune system  
  antibodies, mechanisms, 444  
  APCs, 444  
  humoral and cellular responses, 442–444  
  MHC class I molecules process, 445  
  plasma cells and cytotoxic cells, 444
- ADCC. *See* Antibody-dependent cellular cytotoxicity (ADCC)
- ADCs. *See* Antibody drug conjugates (ADCs)
- Adeno-associated virus (AAV)  
  biology, 487  
  clinical use, 488  
  suitability, gene transfer, 488
- Adenoviruses  
  cellular response, 486  
  characteristics, 486  
  clinical use, 487  
  E1 and E3 regions, 486  
  immunogenicity, 486  
  infection, 485–486  
  RCA, 486  
  serotypes, 484–485  
  “stealth”, 486
- Administration, pharmaceuticals  
  dosage calculations, 230  
  filtration, 230–231  
  flushing solutions, 231  
  osteoporosis treatment, 230  
  prophylaxis to prevent infusion reactions, 231  
  routes, 230
- Adult stem cells  
  bone marrow transplantation, 510–511, 513  
  description, 509, 511  
  HSCs, 509–510, 512  
  mechanisms, 510  
  MSCs, 511  
  “stem cell niche”, 509  
  “transit amplifying” cells, 510
- Age-related macular degeneration (AMD), 243
- AHFS. *See* American Hospital Formulary Service (AHFS)
- Alefacept, 394, 402
- Alemtuzumab  
  antibody accumulation, 338  
  autoimmune  
    diseases, 383  
    hyperthyroidism, 384  
  B-cell chronic lymphocytic leukemia, 382  
  biological activity, 382  
  black box warnings, 339  
  Campath®, 339  
  Campath-1M, 1H and 1G, 382  
  cardiac toxicity, 340  
  CD52, 337, 382  
  CDCC and ADCC, 337, 338  
  clinical trial selection, 339, 340  
  CLL and PLL, 339  
  combination therapy, 339  
  and corticosteroids, 382  
  cytokine, 383  
  dosage modifications, 340  
  dose-escalation schedule, 340–341  
  heart transplantation, 383  
  indications and clinical efficacy, 339, 340  
  induction, 382–383  
  infusion, 383  
  liver transplant, 383  
  low-dose calcineurin inhibitors, 383  
  lung transplant recipients, 383  
  lymphocytes, 382, 383  
  myelosuppression, 340  
  phase I dose-escalation trial, 337  
  plasma and memory type cells, 382  
  premedication, antihistamines, 339  
  steady-state volume, distribution, 338–339  
  subcutaneous administration, 339  
  T-cell depletion, 340  
  thyroid function, 384
- Allergic asthma  
  omalizumab, 406–407  
  SABAs and LABAs, 406  
  symptoms, 406
- Allometric scaling  
  allometric plots, 115  
  description, 114–115

- Allometric scaling (*cont.*)  
 dose prediction, 116  
 hepatic metabolism, 115  
 pharmacokinetic parameters, 115  
 target-mediated drug disposition, 115–116
- AMD. *See* Age-related macular degeneration (AMD)
- American Hospital Formulary Service (AHFS), 225
- AMR. *See* Antibody-mediated rejection (AMR)
- Angiogenesis, 355, 356
- Antibody clearance, MABs  
 elimination, 160–161  
 FcRn receptors, 159  
 humanized MAB, 159–160  
 IgGs, 158–159  
 peptide fragments and amino acids, 158
- Antibody-dependent cellular cytotoxicity (ADCC), 151–152, 154
- Antibody drug conjugates (ADCs), 152–153, 161, 345
- Antibody-mediated rejection (AMR), 385–386
- Anti-drug antibodies (ADA) formation  
 clearing/sustaining effects, 114  
 glomerulonephritis, 113–114  
 immune complex, 114  
 interleukin-6 (IL-6), 114
- Antigen-presenting cells (APCs)  
 class II molecules process, 444  
 lymphocytes, 442  
 phagocytic cells, 442  
 T-cell epitopes, 451  
 T-helper cells (Th-cells), 443, 444
- Antihuman CTLA-4  
 CD152, 353  
 ipilimumab, 353–354  
 lymphoproliferative disorders, 353
- APCs. *See* Antigen-presenting cells (APCs)
- Aptamers, 461–462
- ART. *See* Assisted reproductive technologies (ART)
- Arthritides  
 abatacept, 398  
 adalimumab, 398–399  
 adverse effects, 398  
 belimumab, 401  
 certolizumab pegol, 399  
 clinical diseases, 397  
 corticosteroids and DMARDs, 397  
 development, anti-TNF $\alpha$  agents, 397–398  
 etanercept, 399  
 golimumab, 399  
 infliximab, 399–400  
 rituximab, 400  
 signs and symptoms, 397  
 SLE, 400–401  
 tocilizumab, 400
- Assisted reproductive technologies (ART), 277, 281, 283
- Average cost-effectiveness ratio (ACER), 242–243
- B**
- Bacterial pyrogen, protein formulations  
 excipients, 70  
 exogenous, 69  
 pyrogen removal, 70  
 structure, 69, 70
- Bacteria soluble proteins, 65
- Basiliximab  
 alemtuzumab, 382–384  
 anti-idiotypic IgE anaphylactic reaction, 381–382  
 belatacept, 386–387  
 blood concentrations, 381  
 CD25 receptor inhibition, 381  
 clinical efficacy, 381  
 cyclosporine and corticosteroids, 381  
 dose escalation in adult patients, 381  
 eculizumab, 385–386  
 IL-2 receptor antagonists  
 advantage, 381  
 anti-IL-2, 380  
 immunosuppressive agents, 381  
 infusions, 381  
 murine/human (chimeric) MAB, 381  
 rejections, 381  
 rituximab, 384–385
- Belatacept  
 BENEFIT trial, 386  
 CTLA-4, 386  
 EBV, 387  
 graft survival, 386  
 “immunotolerant” state posttransplant, 386  
 kidney transplant recipients, 386
- Belimumab, 394, 401
- BeneFIX<sup>®</sup>, 307–309
- Bevacizumab  
 angiogenesis inhibitor, 355, 356  
 breast cancer treatment, 347  
 FOLFOX and FOLFIRI, 347  
 GBMs, 349  
 malignant gliomas account, 348  
 metastatic colorectal cancer, 347  
 NSCLC, 347–348  
 pharmacology and pharmacokinetics, 347  
 safety, 349
- Bioassays  
 bioactivity, 42  
 in vitro bioassays, 43  
 thymidine incorporation, dose-response curve, 42, 43
- Biodegradable microspheres  
 dextran-based microsphere technology, SC/IM administration, 84, 85  
 PLGA-based delivery systems, 84  
 PolyActive<sup>™</sup>, 84  
 success factors, 84
- Bioinformatics  
 data mining, 183–184  
 description, 183  
 DNA sequence, 184  
 eBiology, 184  
 information challenges, systems biology, 184  
 “pharmacy informatics”, 184  
 utilization, 184
- Biologics Price Competition and Innovation Act of 2009 (BPCI Act), 250
- Biomarkers  
 description, 187  
 discovery and diagnostic development, 187  
 personalized medicine, 191  
 proteomic research, 185  
 SNPs, 189  
 “theranostic”, 187

- Biophysical and biochemical analysis, recombinant proteins
- analytical techniques
    - bioassays, 42–43
    - blotting techniques, 34–36, 44, 45
    - chromatography, 40–42
    - electrophoresis, 38–40
    - immunoassays, 36–38
    - mass spectrometry, 43–44
  - folding (*see* Folding, recombinant proteins)
  - forces
    - electrostatic interactions, 29
    - hydrogen bond, 29
    - hydrophobic interactions, 29
    - repulsive interactions, 29
    - van der Waals interactions, 29
  - hydration, 29–30
  - primary structure
    - amino acids, 19, 21–22
    - composition, amino acid, 20, 23
    - condensation, 19
    - frequency, occurrence, 20–21, 24
    - granulocyte colony-stimulating factor (G-CSF), 20, 22, 23
    - hydrophobic characteristics, 21, 23
    - L-amino acids, 19, 20
    - nonpolar amino acids, 21
    - peptide bond, 20
    - polar amino acids, 19–20
    - polypeptide sequence, 19
    - primary sequence, 19
  - secondary structure
    - $\alpha$ -helix, 24–26
    - loops and turns, 26–27
    - $\beta$ -sheet, 26
  - stability, 33–34
  - tertiary structure, 27–28
- Bioreactors
- single-use, 51
  - stainless steel, 52
  - transgenic animals and plants, 204
  - types, 49, 66
- Biosensor-pump combinations
- closed-loop systems, 84, 86
  - continuous glucose monitoring (CGM), 85–86
  - PK/PD relationships, 85
  - plasma level and therapeutic effect, 84–85
- Biotechnology. *See also* Medical biotechnology and drug discovery
- chemical genomics, 212–213
  - combinatorial chemistry, 211–212
  - HTS, 210–211
  - modern drug discovery, 210
  - opportunity/technique available, 209
  - recombinant DNA and hybridoma technology, 210
  - hybridoma techniques, 179
  - “omic” (*see* “Omic” technologies)
  - recombinant DNA technology, 179
  - site-directed mutagenesis, 208–209
  - synthetic biology, 209
  - transgenic animals and plants in drugs
- Blood hemostasis models, 299
- Blotting techniques
- biomolecules, 35
  - detection systems, 35–36
  - dot blots/slot blots, 35
  - protein transfer, 35
  - Southern blotting, 35
- Brentuximab vedotin
- ADC, 345
  - AEs, 346–347
  - ALCL, 346
  - ASCT, 346
  - doses, 346
  - FDA, 347
  - Hodgkin’s lymphoma, 346
  - MMAE, 345–347
  - MTD, 346
  - PML, 347
  - QTc interval, 346
- C**
- Cancer
- antihuman CTLA-4, 353–354
  - CD antigens (*see* CD antigens)
  - description, 337
  - EGFR inhibitors (*see* Endothelial growth factor receptor (EGFR) inhibitors)
  - FDA-approved, 337, 338
  - gene therapy
    - benefits, 494
    - correction, genetic mutations, 495–496
    - gene-directed enzyme-prodrug therapy, 498–502
    - immunotherapy, 495
    - nonviral gene therapy, 498
    - oncolytic viruses, 497
    - strategies, 494, 499
    - tumors sensitization, 495
  - RANKL, 354–355
  - stem cells, 520–521
  - tositumomab, 355
  - VEGF inhibitors (*see* Vascular endothelial growth factor (VEGF) inhibitors)
- CAPS. *See* Cryopyrin-associated periodic syndrome (CAPS)
- Carboxy-terminal peptide (CTP), 279, 282, 283
- Cardiovascular diseases, 494, 499–500
- Cascade model, 299, 300
- CBA. *See* Cost-benefit analysis (CBA)
- CDAI. *See* Crohn’s Disease Activity Index (CDAI)
- CD antigens
- alemtuzumab, 337–341
  - brentuximab vedotin, 345–347
  - gemtuzumab, 341–342
  - rituximab, 342–345
- CDC. *See* Complement-dependent cytotoxicity (CDC)
- CEA. *See* Cost-effectiveness analysis (CEA)
- Cell-based model, 299, 300
- Cell therapy, stem cells
- allogeneic and xenogenic therapies, 514
  - ES cells, 515
  - FDA and EMA, 514
  - production and clinical use, SCNT, 515, 516
  - “regenerative medicine”, 514
  - reproductive cloning, “Dolly”, 515, 517
  - treatments, 515
  - use of products, 518–519
  - white blood cells, 514
- Cellular uptake, oligonucleotides
- CPPs, 470
  - delivery systems, 470–471

- Cellular uptake, oligonucleotides (*cont.*)  
  electroporation, tissue, 470  
  exosomes and microvesicles, 471  
  formulations, siRNA, 471  
  grafting, 470  
  lipid modification, siRNA, 470  
  mechanisms, 470  
  miRNA, 471
- Certolizumab pegol, 395, 399, 405
- Cetuximab  
  chimeric IgG<sub>1</sub> MAB, 351  
  CRYSTAL trial, 352  
  EGFR-expressing tumor cells, 351  
  irinotecan-oxaliplatin failure and irinotecan refractory groups, 351  
  KRAS, 352  
  pharmacokinetics, 351  
  safety, 352  
  SCCHN, 352
- CFU. *See* Colony-forming unit (CFU)
- cGMP. *See* Current good manufacturing practice (cGMP)
- Chemical description, insulin  
  51-amino acid protein, 255  
  discrete hexameric complexes, 256  
  human insulin and insulin analog products, 255, 256  
  net charge, 255–256  
  phenolic excipients, 256, 257  
  primary sequence, 255, 256  
  R-state hexamer, 257, 258  
  T-state dimer, hexamer and monomer, 257, 258  
  X-ray crystallographic studies, 257  
  zinc and phenolic, 256, 257
- Chemical genomics, 212–213
- Chemical stability, insulin formulations  
  acidic solution, 267  
  AsnB3, B-chain, 267  
  HMWP, 267–268  
  Lantus<sup>®</sup> and Levemir<sup>®</sup>, 268  
  purity, 267
- Chemistry, manufacturing and controls (CMC) section, 247–248
- Chromatofocusing, 42, 279
- Chromatography  
  adsorption, 59  
  affinity, 59  
  description, 40  
  expanded beds, 61  
  gel-permeation, 60–61  
  HIC, 42  
  hydrophobic interaction, 60  
  immunoaffinity, 60  
  ion-exchange, 42, 59  
  mixed-mode chromatography, 42  
  RP-HPLC, 41–42  
  separation processes, 57  
  size-exclusion, 40–41, 45  
  stationary phases, 58–59
- Chronic kidney disease (CKD), 293, 362
- Chronic lymphocytic leukemia (CLL), 337–339, 368, 384
- Chronic renal insufficiency (CRI), 293
- CKD. *See* Chronic kidney disease (CKD)
- Classical vaccines  
  classification, 446, 447  
  description, 439, 440  
  live attenuated vaccines, 446–448  
  nonliving vaccines, 448
- Colony-forming unit (CFU), 361
- Combinatorial chemistry  
  approaches, 211  
  building blocks, 212  
  combinatorial mix-and-match process, 211, 212  
  HTS, 211  
  and multiple parallel synthesis, 211  
  potential productivity, 211
- Commercial-scale manufacturing, recombinant proteins, 65
- Comparative genomics  
  “biobank”, 183  
  cancer and aid, 183  
  description, 182  
  and functional, 182–183  
  usage, 183
- Complement-dependent cytotoxicity (CDC), 151, 153–154
- Concentrated U-500 beef regular insulin  
  description, 266  
  dosing conversion tables and formulas, 267  
  HbA1c, 267  
  hypoglycemia, 267  
  PK/PD study, 266–267  
  PK serum, 266  
  recombinant human, 266  
  safety, 267
- Contaminants  
  bacteria, 62–63  
  bacterial and nonbacterial hosts derived, 62  
  cellular DNA, 63  
  protein contaminants and product variants, 63–65  
  viruses, 62
- Continuous subcutaneous insulin infusion (CSII), 269
- Cost-benefit analysis (CBA), 242
- Cost-effectiveness analysis (CEA)  
  and ACER, 242–243  
  and AMD, 243  
  and ICER, 243  
  management decisions, 242  
  outcome unit, 242  
  ranibizumab and bevacizumab, 243  
  treatment alternatives/programs, 242
- Cost-minimization analysis, 242
- Cost of illness analysis, 241–242
- Cost-utility analysis (CUA)  
  base case results, 244  
  bevacizumab, 243–244  
  and EPO, 244  
  and ICUR, 244  
  lack of economic savings, 244  
  payers, 244  
  pharmaceutical marketing environment, 244–245  
  and QALY, 243  
  quality differences, 244
- CRI. *See* Chronic renal insufficiency (CRI)
- Crohn’s Disease Activity Index (CDAI), 405, 406

- Cryopyrin-associated periodic syndrome (CAPS)  
  canakinumab, 408  
  description, 394, 396  
  NLRP3 mutations, 408  
  rilonacept, 408–409  
  treatment, 408
- Crystal X-ray diffraction, 251
- CSII. *See* Continuous subcutaneous insulin infusion (CSII)
- CTLA-4. *See* Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
- CTP. *See* Carboxy-terminal peptide (CTP)
- CUA. *See* Cost-utility analysis (CUA)
- Cultivation systems  
  bioreactor systems, 49–51  
  fermentation protocols, 52–53  
  liquid growth medium, 49  
  single-use systems, 49, 51–52
- Current good manufacturing practice (cGMP), 248
- Cutaneous T-cell lymphoma, 355, 356
- Cystic fibrosis (CF)  
  aerosolized tobramycin, 330  
  clinical trials, 329, 330  
  concomitant therapy, 330  
  ESCF data, 330  
  mean FEV<sub>1</sub>, 329  
  potential anti-inflammatory effect, 330  
  safety and deposition, 329–330
- Cytokines  
  chemokines, 413–414  
  chronic viral diseases, 430–431  
  description, 413  
  diagnostic and pharmacological applications, 431  
  growth factors, 413  
  IFNs (*see* Interferons (IFNs))  
  ILs (*see* Interleukins (ILs))  
  magnitude, 431  
  release syndrome, 387–389  
  signaling, 414  
  toxicities, 432
- Cytotoxic T-lymphocyte antigen-4 (CTLA-4), 386
- D**
- Daclizumab  
  dosing, 387, 389  
  structure activity relationship, 387, 389
- Denosumab  
  bisphosphonate therapy, 354  
  bone metastases cause, 354  
  breast and prostate cancer, 354  
  IgG2, 354  
  indications and clinical efficacy, 354–355  
  pharmacology and pharmacokinetics, 354  
  RANK, 354  
  safety, 355  
  SREs, 354
- Development process, MABs  
  *from-bench-to-bedside* process, 155  
  nonclinical activities, 155  
  pharmacokinetics, 156–157  
  preclinical safety assessment, 155–156
- Diagnostic applications, oligonucleotides, 471–472
- Differential scanning calorimetry (DSC), 75
- Diffuse large B-cell (DLBCL), 342
- Diphtheria and tetanus toxoids, 448
- Direct costs, 240–241
- Dispensing biotechnology products  
  administration, 230–231  
  biosimilars, 231  
  educational materials, 232–234  
  handling, 229  
  medical information services  
    provided, 234–235  
  outpatient/home care issues  
    monitoring, 232  
    patient assessment and education, 231–232  
  pharmacists (*see* Pharmacists)  
  preparation, 229–230  
  PVC, 234  
  reimbursement, 232  
  shaking, 234  
  shelf-life, 234  
  storage, 226, 228–229
- Distribution, protein drugs  
  mechanisms and volumes  
    biodistribution studies, 106  
    central compartment, 105–106  
    description, 105  
    epoetin- $\alpha$ , 106  
    as exclusion volume (V<sub>e</sub>), 104–105  
    interstitial space, 105  
    noncompartmental determination, 106  
    radiolabeled studies, 106  
    rate and extent, 104  
    two-compartment pharmacokinetic model, 105  
  protein binding  
    growth hormone, 107  
    metkephamid, 107  
    receptor/ion channel, 106  
    recombinant cytokines, 107  
    receptor-mediated uptake, 107
- Downstream processing (DSP)  
  aseptic techniques, 55  
  biopharmaceutical macromolecule, 55  
  centrifugation, 56–57  
  chromatography, 57–61  
  endotoxin concentration, 55  
  filtration, 56  
  monoclonal antibodies production, 54  
  precipitation, 57  
  process flow, 55, 56  
  scale-up, 55  
  steps, 54, 55
- Drug delivery, rhDNase I, 328–329
- Drug-targeting process, protein  
  carrier-mediated transport, 89  
  causes of failure, 88  
  classes, blood capillaries, 89  
  description, 88  
  developmental stages, 88  
  homing device and “active” parts, 88  
  immunotoxins and immunoliposomes, 96  
  nanoparticles  
    carrier systems, 92  
    EPR effect, 94  
    immunoliposomes, 94–96  
    IV injection, 92–93  
    99mTc-labelled liposomes, 94, 95  
  parameters, particulate carriers, 93

- Drug-targeting process, protein (*cont.*)
- “standard” liposomes, 93–94
  - structures, liposomes, 93
  - passive and active targeting, 89
  - potential and limitations, 88
  - soluble carrier systems
    - bispecific antibodies, 90
    - immunoconjugates, 90–91
    - MAB, 89–90
  - tumor targeting
    - antigen shedding and modulation, 92
    - “bystander” effects, 92
    - factors, 91
    - MAB, 91, 92
    - surface “makeup”, 91–92
- E**
- Eculizumab, 385–386
- Educational materials
- health professionals, 232–233
  - internet and biotech information, 233, 234
  - patients, 233
  - periodical sources, practical information, 232, 233
- Efalizumab
- ADME program, 164
  - CD11a expression, 164
  - determination, SC doses, 166
  - disposition, 165
  - IV administration, 166
  - MOA and PD biomarkers, 163
  - SC administration, 167–168
  - structure, 149, 151
  - surrogates, 164
- Electronic biology (eBiology), 184
- Electrophoresis
- capillary electrophoresis, 39–40
  - 2-D gel electrophoresis, 39, 44, 45
  - IEF, 39
  - PAGE, 38–39
  - protein detection, polyacrylamide gel, 39
- Electrostatic interactions, protein, 29
- Elimination pathways, protein drugs
- disposition modulation, FcRn receptor, 112–113
  - gastrointestinal protein metabolism, 107
  - hepatic protein metabolism, 109–111
  - proteolysis, 107
  - renal/biliary excretion, 107
  - renal protein metabolism, 108–109
  - target-mediated protein metabolism, 111–112
- EMA regulatory framework
- guidance documents, 252
  - guidelines define, 252
  - immunogenicity, 252
  - status, 252–253
- Embryonic stem cells (ESCs)
- extraction, inner cell mass, 512, 513
  - iPS cells, 518, 519
  - maintenance and differentiation, culture, 512, 514
  - pluripotency, 512
  - SCNT, 515
- Endothelial growth factor receptor (EGFR) inhibitors
- cetuximab, 351–352
  - description, 349
  - panitumumab, 352–353
  - pertuzumab, 350–351
  - pharmacodynamic effect, 355
  - trastuzumab, 349–350
  - tyrosine kinase receptors, 349
- Enhanced permeability and retention (EPR) effect, 94
- Enteral administration, peptide and protein drugs, 102
- Enzyme-linked immunosorbent assay (ELISA), 36–38, 44, 45
- EPO. *See* Erythropoietin (EPO)
- Epstein-Barr virus (EBV), 384, 387
- Erythropoiesis-stimulating agents (ESAs), 362
- Erythropoietin (EPO)
- cancer patients and adverse events
    - anemia, 368
    - darbepoetin alfa s.c. dose, 368
    - ESAs therapy, 367
    - hematologic malignancies, 368
    - intrinsic risk, 369
    - iron supplementation, 368
    - MDS, 368
    - multiple myeloma, 368
    - seizures and PRCA, 369
    - serum rHuEPO, 368
    - TIW and QW, 367–368
    - treatment with chemotherapy/corticosteroids, 368
  - and CKD, 362
  - darbepoetin alfa (Aranesp®), 362
  - epoetin alfa (EPOGEN®), 362
  - epoetin zeta and Eprex®, 363
  - and EPOR, 362
  - and ESAs, 362
  - glycosylation, 362
  - and PEG polymer chain, 362
  - pharmacodynamics, 366–367
  - pharmacokinetics, 364–366
  - and RBC production, 361–362
  - regulation, 363–364
  - and rHuEPO (*see* Recombinant human erythropoietin (rHuEPO))
- ESAs. *See* Erythropoiesis-stimulating agents (ESAs)
- ESCs. *See* Embryonic stem cells (ESCs)
- Etanercept
- vs.* adalimumab and infliximab, 402–403
  - efficacy and safety, 399
  - pharmacokinetics, 395
  - p75 human TNF $\alpha$  receptor, 397
  - signs and symptoms, pediatric patients, 399
  - ustekinumab efficacy, 403
- Exon-skipping technique, 462–463, 465
- Expression systems, proteins
- features, biological origin proteins, 48
  - genetically engineered organisms, 47
  - human-derived proteins, 47
  - plants, 48–49
  - transgenic animals, 48
  - yeast cells, 47
- F**
- Fluorescence in situ hybridization (FISH), 355, 356
- Focal segmental glomerulosclerosis (FSGS), 385
- Folding, recombinant proteins
- characterization
    - analytical ultracentrifuge, 32
    - CD, 31
    - dynamic light scattering (DLS), 32
    - hydrodynamic properties, 32

- oligomeric proteins, 32
- sedimentation coefficient, 33
- sedimentation equilibrium, 33
- site-specific chemical modification and proteolytic digestion, 33
- static light scattering, 32
- subvisible and visible particles, 32–33
- temperature dependence, 32
- cosolvents, 31
- dialysis/diafiltration, 30
- disulfide bonds, 30–31
- glycoproteins, 31
- insoluble proteins, 30
- ribonuclease, 31
- unfolded states, 30
- Follicle-stimulating hormone (FSH)
  - and ART, 277
  - CHO cell line, 277
  - drug products, 277
  - estrogens and LH, 277
  - glycoprotein hormone, 277–279
  - IVF/ICSI, 277
  - preparations, 277
  - receptor, 277
  - recombinant (*see* Recombinant FSH)
- Formulations, protein. *See* Protein formulations
- Freeze-drying, protein formulations
  - crystallizing water, 73
  - excipients, 73
  - stability requirements, 72
  - stages, 73
- FSH. *See* Follicle-stimulating hormone (FSH)
- Functional genomics
  - “biobank”, 183
  - cancer and aid, 183
  - and comparative genomics, 182–183
  - description, 182
  - microarray analysis, 187
  - and proteomics, 185
  - therapeutic clinical outcomes, 182
- Fusion tags, 478, 480
- G**
- Gastrointestinal protein metabolism, 107
- G-CSF. *See* Granulocyte colony-stimulating factor (G-CSF)
- Gemtuzumab
  - GO, 341
  - Mylotarg®, 341
  - post approval clinical trial, 341–342
  - SOS, 342
- Gemtuzumab ozogamicin (GO), 341–342
- Gene expression, oligonucleotides
  - antisense molecules
    - alicaforsen, 466–467
    - clinical trials, 467, 468
    - fomivirsen, 466
    - medical applications, 464–465
    - mRNA-blocking, 465
    - mRNA-cleaving, 465–466
    - RNase H, 466
  - ribozymes and DNazymes, 466, 467
  - RNase P, 467
  - siRNA/miRNA
    - ALN-RSV01, 469
    - PCSK9, 469
    - rapid progress, 467–468
    - REDD1, 468–469
    - RNA interference, 466, 467
    - stem-loop structures, 467
    - transcription factor decoys, 464, 466
    - triple helix formation, 464
- Gene repair and chromosomal change, oligonucleotides
  - eukaryotes, 462
  - exon-skipping technique, 462–463, 465
  - ribonucleoprotein inhibition, 463–464
  - transcription and translation, 462, 463
  - triple helix formation, 462–464
- Gene therapy
  - cancer (*see* Cancer, gene therapy)
  - cardiovascular diseases, 494, 499–500
  - gene transfer systems, 477–480
  - geographical distribution, clinical trials, 494, 495
  - infectious diseases, 494, 500
  - methods, administration, 477, 478
  - monogenetic diseases, 499
  - neurological diseases, 494–496, 500
  - nonviral vectors, 488–492
  - potential use, nucleic acids, 477
  - products, regulatory issues, 500–501
  - SCID, 477
  - small molecule drugs, 477
  - stem cells (*see* Stem-cell-based gene therapy)
  - viral vectors, 480–488
- Gene transfer systems, plasmid components
  - bacterial elements, 478
  - description, 477–478
  - fusion tag, 480
  - introns, 480
  - MCS and UTR, 480
  - polyadenylation (polyA) sequence, 480
  - TRE, 478–479
- Genome-wide association studies (GWAS)
  - description, 189
  - genetic variats, 195
  - personalized medicine, 189–190
  - SNPs and drug response/major disease, 189
- Genomics
  - comparative, 182–183
  - description, 180
  - drug targets, 180–181
  - functional (*see* Functional genomics)
  - HGP (*see* Human Genome Project (HGP))
  - NGS, 182
  - structural (*see* Structural genomics)
- GHD. *See* Growth hormone deficiency (GHD)
- GHRH. *See* Growth hormone releasing hormone (GHRH)
- Glycomics/glycobiology
  - application, 197
  - glycoforms, 198
  - glycosylation, 198
  - medicine, 198
  - protein-based medicinal agents, 197
  - saccharides/sugars and derivatives, 197–198
- Glycoprotein hormone
  - and assembly, 278
  - bisecting GlcNAc residues, 278
  - CTP, 279
  - description, 277
  - FSH three-dimensional model, 278
  - hCG, 278–279
  - heterodimeric protein, 277–278

- Glycoprotein hormone (*cont.*)  
 N-linked carbohydrates, 278  
 oligosaccharides, 278  
 polypeptide backbones, 278
- Glycosylated single-chain polypeptides, 361
- Glycosylation  
 antigenicity, 135  
 asparagine, 5  
 carbohydrate heterogeneity, 64  
 darbepoetin, 64  
 definition, 5  
 and medicine, 198  
 protein, 66, 197  
 therapeutic proteins, 135
- GM-CSF. *See* Granulocyte macrophage colony-stimulating factor (GM-CSF)
- Granulocyte colony-stimulating factor (G-CSF)  
 characteristics, 369  
 chemotherapy-induced neutropenia, 370  
 filgrastim, 369  
 and GM-CSF, 369  
 lenograstim, 369  
 pegfilgrastim, 369–370  
 polypeptide, 369
- Granulocyte macrophage colony-stimulating factor (GM-CSF), 228, 370
- Growth hormone deficiency (GHD), 288, 292, 294
- Growth hormone releasing hormone (GHRH), 286, 287
- GWAS. *See* Genome-wide association studies (GWAS)
- H**
- HACA. *See* Human anti-chimeric antibodies (HACA)
- HAHA. *See* Human antihuman antibody (HAHA)
- HAMA. *See* Human anti-mouse antibodies (HAMA)
- Handling  
 mixing and shaking, 229  
 travel requirements, 229
- hCG. *See* Human chorionic gonadotropin (hCG)
- $\alpha$ -Helix structure, protein, 24–27
- Hematopoiesis, 361
- Hematopoietic growth factors (HGF)  
 and activities, 361, 362  
 blood cells, 361  
 carbohydrate, 361  
 and CFU, 361  
 description, 361  
 different mature blood cells h, 361  
 and EPO (*see* Erythropoietin (EPO))  
 glycoproteins, 371  
 glycosylated single-chain polypeptides, 361  
 myeloid (*see* Myeloid HGF)  
 rhEPO, 371–372  
 rhG-CSF, 371  
 rhGM-CSF, 371  
 rhSCF, 371, 372
- Hematopoietic stem cells (HSCs), 509, 510, 512
- Hematopoietins  
 IL-11, 422–423  
 IL-13, 423  
 IL-34, 423–424  
 IL-8 and IL-16, 423  
 IL-31 and IL-32, 423  
 IL-3, IL-5 and IL-6, 422
- Hepatic protein metabolism  
 as cholecystokinin-8 (CCK-8), 109  
 direct shuttle/transcytotic pathway, 111  
 glycoproteins, 110–111  
 lipoprotein receptor-related protein (LRP), 111  
 mechanisms, 109, 110  
 proteolysis, 109  
 receptor-mediated endocytosis, 110  
 uptake, 110
- HGF. *See* Hematopoietic growth factors (HGF)
- hGH. *See* Human growth hormone (hGH)
- hGH receptor (GHR), 287
- High molecular weight protein (HMWP), 267–268
- High-throughput screening (HTS)  
 description, 211  
 enzyme inhibition and radioligand binding assays, 211  
 in vitro screening, 210–211  
 recombinant DNA technology, 210  
 synthetic compounds, 211
- HLA. *See* Human leukocyte antigens (HLA)
- HMWP. *See* High molecular weight protein (HMWP)
- HSA. *See* Human serum albumin (HSA)
- HSCs. *See* Hematopoietic stem cells (HSCs)
- HTS. *See* High-throughput screening (HTS)
- Human anti-chimeric antibodies (HACA), 149
- Human antihuman antibody (HAHA), 149–150
- Human anti-mouse antibodies (HAMA), 89, 149, 379
- Human chorionic gonadotropin (hCG), 278, 279
- Human deoxyribonuclease I (DNase I)  
 description, 321  
 rhDNase I (*see* Recombinant human DNase I (rhDNase I))  
 synthesis, 321
- Human Genome Project (HGP)  
 DNA sequencing approaches, 181  
 genetic resolution, 181  
 goal of, 181  
 sequencing efficiency, 182  
 and structural genomics, 181–182
- Human growth hormone (hGH)  
 clinical usage  
 cardiovascular recovery and function, 294  
 CKD, 293  
 CRI, 293  
 deficient adults populations, 294  
 effects in burns, 294  
 GHD, 292  
 ISS, 292–293  
 levels and IGF decline, 294  
 malnutrition and wasting syndromes, 294  
 Noonan syndrome, 293  
 PWS, 293  
 safety, 295  
 SGA, 293  
 SHOX gene, 293–294  
 TS, 293  
 description, 285  
 3-D structure, antiparallel alpha-helical regions, 285, 286  
 endogenous growth hormone, 285  
 hGH-N gene and hGH-V gene, 285  
 IGF-1 production, 296  
 liver disease, 295–296  
 metabolism, 285  
 pharmacology (*see* Pharmacology, hGH)  
 pit-hGH, 285  
 primary structure, rhGH, 285, 286

- protein
    - commercially available hGH preparations, 289–291
    - liquid formulations, rhGH, 292
    - lyophilized formulations, 292
    - rhGH products, 289, 292
    - Serostim<sup>®</sup>/Saizen<sup>®</sup>/Zorbtive<sup>®</sup>, 289
  - sequential dimerization, 295
  - Human leukocyte antigens (HLA), 377
  - Human serum albumin (HSA), 228
  - Hydration, recombinant proteins, 29–30
  - Hydrogen bonds, protein, 29
  - Hydrophobic interactions, protein, 29
- I**
- IBD. *See* Inflammatory bowel disease (IBD)
  - ICER. *See* Incremental cost-effectiveness ratio (ICER)
  - ICSI. *See* Intracytoplasmic sperm injection (ICSI)
  - ICUR. *See* Incremental cost-utility ratio (ICUR)
  - Idiopathic short stature (ISS), 292–293
  - IFNs. *See* Interferons (IFNs)
  - ILPS. *See* Insulin lispro protamine suspension (ILPS)
  - IL-2 receptor antagonists
    - animal IL-2 knockout models, 379–380
    - CD25, 380
    - description, 379
    - murine lymphocytes, 380
    - single gene locus, chromosome 4, 379
    - T-cell receptor, 380
  - ILs. *See* Interleukins (ILs)
  - Immune thrombocytopenia purpura (ITP), 371
  - Immunoassays, ELISA, 36–38
  - Immunogenicity
    - ADA formation, 113–114
    - description, 252
    - and protein pharmacokinetics, 114
    - therapeutic proteins
      - antigenicity, 135, 136
      - assays for antibodies, 137–138
      - awareness, 140
      - description, 134, 135
      - dose, 136
      - formulation, 136, 137
      - glycosylation, 135
      - immunological response, B cells, 134
      - impurities, 136
      - induced antibodies, 139
      - monoclonal antibodies, 138
      - patient features, 136–137
      - plasma-derived clotting factors and growth hormone, 133
      - porcine and bovine insulins, 133
      - predictors, 139–140
      - quality controls and regulatory system, 133
      - recombinant DNA-derived protein, 133–134
      - route of administration, 136
  - Immunological response, vaccination
    - activation and migration, 442
    - active and passive immunization, 440, 441
    - adaptive immune system, 442–445
    - APCs and lymphocytes, 442
    - generation, 440–441
    - memory cells, 440
    - mimicking, infection, 440
    - PRRs and PAMPs, 442
    - route of administration, 445–446
    - vaccine design, 445, 446
  - Incremental cost-effectiveness ratio (ICER), 243
  - Incremental cost-utility ratio (ICUR), 244
  - Indirect costs, 241
  - Induced pluripotent stem (IPS) cell technology
    - chromosomal defects, 518
    - discovery, regenerative medicine, 516
    - mouse skin fibroblasts, 515
    - Parkinson's disease, 519, 520
    - sickle cell anemia, mice, 516, 518
  - Infectious diseases, 494, 500
  - Inflammatory bowel disease (IBD), 403–405
  - Inflammatory diseases
    - allergic asthma, 406–407
    - arthritis (see Arthritides)
    - CAPS, 408–409
    - conventional drugs, 393
    - glycoproteins, 393
    - multiple sclerosis (MS), 407–408
    - pharmacokinetic and mechanistic properties, 393–397
    - psoriasis, 401–406
  - Infliximab
    - biologic activity, TNF $\alpha$ , 399
    - Crohn's disease, 405–406
    - description, 397–398
    - efficacy and safety, 399–400
    - pharmacokinetics, 395, 396, 405
    - signs and symptoms, 400
  - INN. *See* International Nonproprietary Names (INN)
  - Insulin
    - administration, 76
    - albumin, 71
    - as anti-aggregation agents, 71
    - chemical description, 255–257
    - chemical stability, 267–268
    - concentrated formulations, 266–267
    - CSII, 269
    - dosing, 271
    - extemporaneous mixing, 271
    - fraction, 78–79
    - and glucose profiles, 257, 259
    - injection devices, 269
    - intermediate-acting insulin preparations, 264–265
    - long-acting formulations
      - absorption rate, 265
      - adequate basal insulin levels, 265
      - degludec, 266
      - detemir (Levemir<sup>®</sup>), 265–266
      - glargine (Lantus<sup>®</sup>), 265
      - hexamers, 266
      - hypoglycemia, 266
      - LY2605541 and LY2963016, 266
      - PK profile, "mealtime" insulin formulation, 265
      - tetradecanoyl-acylated insulin to albumin, 266
    - nondiabetic person falls, 257
    - noninvasive delivery, 270
    - pancreatic response, 257
    - phospholipids and surfactants, 71
    - physical stability, 268–269
    - purification, 255
    - rate-controlled delivery, 82
    - rDNA technology, 255
    - regular and rapid-acting soluble preparations
      - Apidra<sup>®</sup> and Humalog<sup>®</sup>, 263
      - Asn<sup>A21</sup>, 257
      - design strategy, Asp<sup>B28</sup>-human, 263
      - dissociation after subcutaneous administration, 259, 261

- Insulin (*cont.*)
- glutamic acid substitution, 263
  - human-based U-100 insulin analog formulations, 259, 261–262
  - infusion tubing, 263
  - insulin lispro, 259, 263
  - neutral U-100 insulin formulations, 257, 260
  - pharmacodynamic profile, soluble formulation (type R), 257
  - pump systems, 263
  - rapid action, 263
  - T1DM/T2DM, 263
  - zinc and phenolic preservatives, 257
- resuspension, 270–271
- reversible self-association, 71
- storage, 270
- ultrapid initiatives, 263–264
- vial presentations, 269
- Insulin lispro protamine suspension (ILPS), 264, 269
- Intangible costs, 241
- Interferons (IFNs)
- description, 413
  - helical cytokine, 414
  - human, HGNC, 415, 416
  - IFN- $\alpha$  therapeutics
    - alfa-2a, 424
    - “influenza-like symptoms”, 425
    - Intron A<sup>®</sup> and Infergen<sup>®</sup>, 425
    - recombinant, 424
    - Roferon<sup>®</sup> A, 425
  - IFN- $\beta$  products, 425–426
  - IFN-g, Actimmune<sup>®</sup>, 426
  - JAK-STAT signaling pathway, 414–415
  - PEGylated
    - biopharmaceuticals, 430, 431
    - intraprotein bridges, 429
    - linear structures, 429
    - proteins, 428–429
    - rhIFN- $\alpha$  and IFN alfa-2 $\alpha$ , 429–430
  - type I and II, 415
- Interleukins (ILs)
- databases, 418
  - description, 413
  - hematopoietins, 422–423
  - IL-17 and IL-25, 422
  - IL-1 family
    - IL-36 A, B and G, 418–419
    - IL-18 and IL-33, 418
    - IL-37 and IL-38, 419
    - IL-1 and IL-1Ra, 418
    - IL-36RN, 419
  - IL-2 family
    - IL-9, 419–420
    - IL-15 and IL-21, 420
    - IL-2, IL-4 and IL-7, 419
  - IL-10 family
    - helical cytokines, 414, 420
    - IL-22, 420–421
    - IL-28A, IL-28B and IL-29, 421
    - IL-24 and IL-26, 421
    - IL-10, IL-19 and IL-20, 420
  - IL-12 family
    - IL-35, 421–422
    - IL-12, IL-23 and IL-27, 421
  - inflammatory response, 415
  - Kineret<sup>®</sup> (anakinra), 428
  - names and symbols, HGNC, 415–417
  - Neumega<sup>®</sup> (oprelvekin), 427–428
  - pathogenic agents, 415
  - Proleukin<sup>®</sup> (aldesleukin), 427
- International Nonproprietary Names (INN), 277, 282
- Intracytoplasmic sperm injection (ICSI), 277, 281
- Introns, 478, 480
- In vitro activity, CF sputum
- action mechanism, 325
  - depolymerization, filamentous actin (F-actin), 325–326
  - magnesium ions, 325
  - mucus transport properties, 325
  - nacystelyn, 325
  - pourability assay, 325
  - reduce sputum viscoelasticity, 326, 327
  - reduction in size, 325, 326
  - viscoelastic properties, 325
  - viscosity reduction, 325
- In vitro fertilization (IVF), 277, 281
- In vivo activity, CF sputum
- direct characterization, apparent DNA size, 326, 327
  - immunoreactive concentrations and enzymatic activity, 326, 328
  - viscoelasticity, 326
- Iodine-131 (<sup>131</sup>I) tositumomab, 342–345
- Ipilimumab
- indications and clinical efficacy, 353
  - pharmacology and pharmacokinetics, 353
  - safety, 353–354
- IPS cell technology. *See* Induced pluripotent stem (IPS) cell technology
- ISS. *See* Idiopathic short stature (ISS)
- ITP. *See* Immune thrombocytopenia purpura (ITP)
- IVF. *See* In vitro fertilization (IVF)
- K**
- Knockout mice
- animal disease models, 207
  - apoptosis E, 207
  - four-step process, 206–207
  - gene-targeted knockout mouse, 206
  - genetic engineering, 208
  - “humanized mice”, 207
  - null allele, 206
  - programs, 207
- L**
- Lactate dehydrogenase (LDH), 353
- Lanotepase, 316
- Lantus<sup>®</sup>, 265, 268
- Lentiviruses, 484
- Levemir<sup>®</sup>, 265–266, 268
- LH-RH. *See* Luteinizing hormone-releasing hormone (LH-RH)
- Lipidomics, 198
- Lipoprotein receptor-related protein (LRP), 311, 315
- Live attenuated vaccines, 446–448
- Live vectored vaccines
- adenoviruses, 449
  - bacteria and viruses, 449
  - description, 448–449
  - prevalence, preexisting immunity, 450
  - vaccinia virus, 449, 450
- LRP. *See* Lipoprotein receptor-related protein (LRP)

- Luteinizing hormone-releasing hormone (LH-RH)  
  cetorelix, 123  
  complex modeling approach, 123  
  glomerular filtration, 108  
  IV administration, 103
- M**
- MAB. *See* Monoclonal antibodies (MABs)
- MAB-drug interactions  
  ado-trastuzumab emtansine (T-DM1) and  
    pertuzumab, 161  
  clinical methods, 162  
  cyclosporin A (CsA), 161  
  cytochrome P450 (CYP) enzymes, 161  
  methotrexate (MTX), 161  
  PK/PD, 162–163  
  small molecule drugs, 161
- MABs. *See* Monoclonal antibodies (MABs)
- Macrophage colony-stimulating factor (M-CSF)  
  kidneys, target-mediated drug disposition, 108  
  linear pharmacokinetics, 111, 113
- Major histocompatibility complexes (MHC), 377
- MALDI. *See* Matrix-assisted laser desorption (MALDI)
- Mass median aerodynamic diameter (MMAD), 329
- Mass spectrometry  
  MALDI, 44  
  peptide map, pepsin digest, 43  
  post-translational modifications, 43  
  “protein fingerprint”, 44
- Master cell bank (MCB), 279
- Matrix-assisted laser desorption (MALDI), 44
- MCB. *See* Master cell bank (MCB)
- MCS. *See* Multiple cloning sites (MCS)
- Mechanical pumps  
  characteristics, ideal pump, 82, 83  
  controlled administration, 83  
  failures, 82–83
- Medical biotechnology  
  Activase®, 238  
  analysis, pharmaceutical market, 238  
  clinical research protocol, 239  
  costs association, 239  
  documenting and understanding, 238  
  evaluation, product, 237  
  generalized model, value, 239  
  health care finance, 237  
  licensing, new agents, 237  
  marketing focus, 237–238  
  Neupogen®, 238  
  pharmaceutical technologies, 238  
  pharmacoeconomics (*see* Pharmacoeconomics)  
  treatment, disorders, 239  
  value, 238, 239
- Megakaryocytopoiesis  
  Peg-MGDF, 370  
  romiplostim (Nplate®), 370–371  
  TPO, 370
- Mesenchymal stem cells (MSCs), 492–493
- Metabolomics  
  description, 188  
  high-performance liquid chromatography,  
    187–188  
  metabolites, 187
- Metabonomics, 188
- MHC. *See* Major histocompatibility complexes (MHC)
- Microarrays  
  array technology, 187  
  biochips, 185–186  
  DNA, 186  
  oligonucleotide, 186–187  
  Roche Diagnostics AmpliChip CYP 450, 186
- Microencapsulated secretory cells  
  antibodies, 88  
  implantation, Langerhans cells, 87
- Mitogen-activated protein kinase (MAPK) pathway, 370
- MMAD. *See* Mass median aerodynamic diameter (MMAD)
- Modern vaccine technologies  
  cancer vaccines, 453  
  description, 439, 440  
  drug abuse, 453  
  genetically attenuated microorganisms, 448  
  live vectored vaccines, 448–450  
  nucleic acid vaccines, 451, 452  
  recombinant peptide and protein vaccines, 450  
  reverse vaccinology, 451–452  
  synthetic peptide-based vaccines, 450–451  
  systems biology, 453
- Molecular biotechnology  
  amino acid sequence, insulin, 1, 2  
  ampicillin, G418, and HAT medium selection, 17, 18  
  economics and use  
    CF and GSD II, 3  
    development cost, 2  
    monoclonal antibodies, 2–3  
  human histone H4 protein, *E. coli*, 16–17  
  *in silico* DNA sequence to therapeutic protein  
    cell culture, 12  
    cloning PCR products, 8–9  
    copyDNA, 5–8  
    DNA sequence, 4  
    expression host selection, 4–5  
    purification, 12, 13  
    selection, 4  
    steps, 3  
    transfection, 9–12  
  monoclonal antibodies (*see* Monoclonal antibodies)  
  pharmaceutical (*see* Pharmaceuticals, biotechnology)  
  transformation efficiency, 16, 17
- Molecular cloning, definition, 4
- Monoclonal antibodies (MABs)  
  abciximab and ranibizumab, 152  
  absorption, 157  
  adalimumab and panitumumab, 150  
  ADCC, 153, 154  
  ADCs and RIT agents, 152–153  
  advantage, 387, 388  
  annual production, 15  
  antibody clearance, 158–161  
  apoptosis, 154–155  
  bispecific, 90  
  in cancer (*see* Cancer)  
  CDC, 153–154  
  classes, immunoglobulin (Ig), 149, 150  
  direct modulation, target antigen, 153  
  distribution, 157–158  
  drug research and development, 143  
  efalizumab (*see* Efalizumab)  
  Fab, F(ab')<sub>2</sub> and scFv, 152  
  Fc regions, 151–152  
  gemtuzumab ozogamicin, 153  
  half-life of Fc, 152

- Monoclonal antibodies (MABs) (*cont.*)  
   and HAMA, 89  
   HAMA and HACA, 149  
   homing ability, 89  
   humanization, 89–90  
   humanized antibodies, 15, 16  
   humanized  $V_L$  and  $V_H$  region, 15, 16  
   hybridoma technology, 143  
   ibritumomab tiuxetan and tositumomab, 153  
   IgG1 structure, 89, 90, 149, 151  
   immunization process, 14, 15  
   immunoconjugates, 90, 91, 171  
   immunogenicity, 138  
   immunogenicity problem, 89  
   MAB-drug interactions, 161–163  
   metabolism, 172  
   MOA and PD biomarkers, 163  
   PCR sewing, 15  
   pharmacological properties, 143–148  
   properties, 172  
   solid organ transplantation (*see* Solid organ transplantation)  
   structural components, 151  
   surrogate molecules, 164  
   technological evolutions, 143  
   transgenic mice, 90  
   translational medicine/development process  
     (*see* Development process, MABs)  
   trastuzumab, 149–150  
   in tumor targeting, 91, 92
- Monogenetic diseases, 494, 495, 499  
 Monomethyl auristatin E (MMAE), 345  
 MS. *See* Multiple sclerosis (MS)  
 MSCs. *See* Mesenchymal stem cells (MSCs)  
 Multiple cloning sites (MCS), 478, 480  
 Multiple sclerosis (MS), 396, 407–408  
 Muromonab  
   acute and chronic adverse effects, 379  
   CD3 receptor, 378  
   cytokine release syndrome, 379  
   description, 378  
   Epstein-Barr viral B-cell malignant transformation, 379  
   HAMA, 379  
   immunodepleting potency, 379  
   induction agent, 378  
   kidney transplant recipients, 378  
   liver recipients, 378  
   murine monoclonal antibody, 378  
   polyclonal antibody-resistant rejections, 379  
   posttransplant lymphoproliferative disease, 379  
   renal function, 378  
   viral infections, 379  
 Muromonab-CD3 (OKT3), 375  
 Myeloid HGF  
   and G-CSF, 369–370  
   GM-CSF, 370  
   megakaryocytopoiesis, 370–371  
   pathway, 371  
   and SCF, 370
- N**
- Natalizumab  
   annualized relapse rate (ARR), 407  
   clinical response and remission, 406  
   efficacy and safety, 406  
   IBD, 404  
   pharmacokinetics, 396  
   PML, 407–408  
 Nebulizers, 329  
 Neurological diseases, 494–496, 500  
 Neutral protamine Hagedorn (NPH)  
   activity duration, 264  
   clinical data, 265  
   crystalline suspension, 264  
   immunogenicity issues, 265  
   NPL and ILPS, 264  
   protamine, 264  
   rapid-acting insulin analog, 264  
   suspension, insulin lispro, 264  
   T2DM patients, 264  
 Neutral protamine lispro (NPL), 264  
 Next-generation genome sequencing (NGS)  
   comparative genomics, 183  
   and \$1,000 genome, 182  
   genotyping, 182  
   toxicogenomics, 197  
 NGS. *See* Next-generation genome sequencing (NGS)  
 Non-cystic fibrosis respiratory disease, 330–331  
 Non-Hodgkin's lymphoma, 342  
 Nonliving vaccines, 447, 448  
 Non-small-cell lung cancer (NSCLC), 243–244,  
   347–348  
 Nonviral gene therapy  
   barriers, 488, 489  
   cationic lipids, 491  
   clinical use, 492  
   description, 488  
   peptides, 491  
   physical methods  
     description, 489–490  
     electroporation, 489  
     microinjection, 488  
     particle bombardment, 488–489  
   polymers, 491–492  
 Noonan syndrome, 293  
 NPH. *See* Neutral protamine Hagedorn (NPH)  
 NPL. *See* Neutral protamine lispro (NPL)  
 NSCLC. *See* Non-small-cell lung cancer (NSCLC)  
 Nuclear factor kappa B (NF- $\kappa$ B) pathway, 370  
 Nucleic acid vaccines, 451, 452, 456  
 Nutrigenomics, 198–199
- O**
- Oligonucleotides  
   cellular uptake, 470–471  
   characteristics, 459  
   chemical modifications, 472–473  
   description, 459  
   diagnostic applications, 471–472  
   gene expression, 464–469  
   gene repair and chromosomal change, 462–464  
   modifications, 459, 460  
   non-nucleic acids  
     aptamers/riboswitches, 461–462  
     description, 459–460  
     dsRNA, 462  
     prokaryotic DNA, 462  
   pharmacokinetics, 469  
   stability, 469–470  
   therapeutic effects, 459  
   Vitravene® and Macugen®, 472

- Omalizumab, 396, 406–407  
 “Omic” technologies  
   bioinformatics (*see* Bioinformatics)  
   biomarkers (*see* Biomarkers)  
   cellomics, 199  
   DNA structure and function, 180  
   genomics (*see* Genomics)  
   glycomics/glycobiology, 197–198  
   interactomics, 199  
   lipidomics, 198  
   metabonomics and metabolomics, 187–188  
   microarrays, 185–187  
   new drug discovery, genomic strategy, 179, 180  
   novel therapeutics, 180  
   nutrigenomics, 198–199  
   personalized medicine (*see* Personalized medicine)  
   pharmacogenetics (*see* Pharmacogenetics)  
   pharmacogenomics (*see* Pharmacogenomics)  
   proteomics (*see* Proteomics)  
   systems biology, 199  
   toxicogenomics, 196–197  
   transcriptomics, 184–185  
 Oncolytic viruses, 499  
 Opportunity costs, 241  
 Osmotically driven systems  
   Alzet osmotic mini-pump, 83, 84  
   protein solution, 83  
   rate-deter-mining process, 83
- P**  
 PAMPs. *See* Pathogen-associated molecular patterns (PAMPs)  
 Panitumumab  
   mean progression-free survival, 353  
   PACCE, 353  
   pharmacology and pharmacokinetics, 352  
   randomized phase III trial, 352–353  
   safety, 353  
 Parenteral administration  
   definition, 75  
   peptide and protein drugs  
     anakinra, etanercept, insulin, and pegfilgrastim, 104  
     apparent absorption rate constant, 104  
     bioavailability assessments, 103–104  
     intramuscular (IM), 103, 104  
     intravenous (IV), 103  
     monoclonal antibodies and fusion proteins, 104  
     routes of, 102–103  
     subcutaneous (SC), 103, 104  
   protein delivery, 76  
 Pathogen-associated molecular patterns (PAMPs), 441, 442  
 Pattern recognition receptors (PRRs), 441, 442, 445, 454  
 PBMs. *See* Pharmacy benefits management companies (PBMs)  
 PDMDD. *See* Pharmacodynamic-mediated drug disposition (PDMDD)  
 Personalized medicine  
   application, pharmacogenetics, 194  
   challenges, 194–195  
   drug pharmacodynamics, genomic variation, 193–194  
   drug pharmacokinetics, genetic variation, 192–193  
   epigenetics/epigenomics, 195–196  
   hopes and realities, 190  
   individualized optimized pharmacotherapy, 190–191  
   “omic” technologies, role, 190, 191  
   pharmaceutical care, 191–192  
   pharmacogenomics, 190  
   pharmacy education curricula, 190  
   SNPs, 191  
   targeted therapy, 192  
   trastuzumab, 194  
 Pharmaceuticals  
   biotechnology  
     biopharmaceuticals, 1  
     therapeutic proteins, 1, 2  
   vaccines  
     adjuvants, immune potentiators and delivery systems, 454  
     characterization, 455  
     combination vaccines, 454  
     production, 453–454  
     storage, 455  
 Pharmacists  
   agents, 223  
   and biotech drug handling, 225, 227–228  
   biotechnology drugs, 223  
   delivery routes, 224  
   description, 223  
   expertise in areas, 224  
   information sources, 225, 226  
   information types, 224–225  
   medicare benefit policy manual outlines, 223  
   novel protein products, 224  
   pharmaceutical care services to patients, 223  
   physicians, 224  
 Pharmacodynamic-mediated drug disposition (PDMDD), 366  
 Pharmacodynamics  
   EPO  
     CFU-E cells, 366  
     darbepoetin alfa, 366–367  
     erythroid progenitor cells, 367  
     iron deficiency, 367  
     mechanisms, 367  
     oxygen feedback mechanism, 367  
     PK/PD relationships, 367  
     RBC life span, 366  
   protein therapeutics  
     characterization, 101  
     description, 101  
     dose-concentration-effect relationship, 101, 102  
     PK/PD modeling (*see* Pharmacokinetic-pharmacodynamic modeling (PK/PD modeling))  
 Pharmacoeconomics  
   assessment, 240  
   biotechnology industry, 240  
   CBA, 242  
   CEA, 242–243  
   clinical studies assess, 239–240  
   cost-minimization analysis, 242  
   cost of illness analysis, 241–242  
   CUA, 243–245  
   definition, 239  
   direct costs, 240–241  
   disease management, 240  
   economic analysis, 240  
   economic evaluation methodologies, 241  
   health economists, 240  
   indirect costs, 241  
   intangible costs, 241  
   opportunity costs, 241  
   orphan drugs, 240  
   pharmaceutical and biotechnology products, 239

- Pharmacogenetics  
 ADRs, 192  
 analysis of patients, 194  
 application, 194  
 drug metabolism and transport, 192  
 personalized medicine, 188, 190  
*vs.* pharmacogenomics, 189  
 polymorphisms, 192  
 SNPs (*see* Single-nucleotide polymorphisms (SNPs))  
 toxicogenomics, 196–197
- Pharmacogenomics  
 analysis of patients, 194  
 demonstration projects, 190  
 FDA-approved drugs, 191  
 genetic variations, 190  
 GWAS (*see* Genome-wide association studies (GWAS))  
 personalized medicine, 188, 190  
*vs.* pharmacogenetics, 189  
 tests, 190  
 toxicogenomics, 196  
 warfarin drug action and ADR, 193
- Pharmacokinetic-pharmacodynamic modeling (PK/PD modeling)  
 application, 118  
 approaches, 117, 118  
 cell life span models  
 description, 121–122  
 erythropoietin (EPO), 122, 123  
 process, erythropoiesis, 122, 123  
 reticulocyte, RBC and Hb, 122, 123  
 complex response models  
 application, 124, 125  
 cetorelix, 123–125  
 concentration and ANC time profiles, pegfilgrastim, 126, 127  
 cytokinetic model, 124  
 granulopoietic effects, pegfilgrastim, 124, 126  
 LH-RH, 123–124  
 description, 116–117  
 direct link models  
 IgE antibody CGP 51901, 118–119  
 plasma concentrations, 118  
 exposure and response, 117–118  
 indirect link models  
 concentration-effect relationship, 119  
 hypothetical effect compartment, 119–120  
 tissue distribution, 120  
 trastuzumab exposure, 120  
 indirect response models  
 description, 121  
 elaboration, 121  
 SB-240563 evaluation, 121, 122  
 time courses, plasma concentration, 120–121  
 mechanism-based, 117
- Pharmacokinetics  
 EPO  
 absorption, 364  
 bioavailability, 364  
 distribution, 365  
 elimination, 365–366  
 protein therapeutics  
 absorption, 102–104  
 characterization, 101  
 chemical modifications, 116  
 description, 101  
 distribution (*see* Distribution, protein drugs)  
 dose-concentration-effect relationship, 101, 102  
 elimination (*see* Elimination pathways, protein drugs)  
 and immunogenicity, 113–114  
 insulin, 102  
 species specificity and allometric scaling, 114–116
- Pharmacokinetics/pharmacodynamics (PK/PD)  
 clinical development, 162–163  
 description, 168, 169  
 efalizumab (*see* Efalizumab)  
 and efficacy data, 168, 171  
 human, prediction, 162  
 population, 169–170
- Pharmacology, hGH  
 biologic actions, 286–287  
 dosing schedules and routes, 288–289  
 metabolism, 289  
 molecular endocrinology and signal transduction, 288  
 pharmacokinetics, 289  
 receptor and binding proteins, 287  
 secretion and regulation, 285–287
- Pharmacy benefits management companies (PBMs), 225  
 Pharmacy informatics, 184, 190  
 Phosphatidylinositol 3-kinase (PI3K) pathway, 370  
 Physical stability, insulin formulations, 268–269  
 PK/PD. *See* Pharmacokinetics/pharmacodynamics (PK/PD)  
 PML. *See* Progressive multifocal leukoencephalopathy (PML)  
 Polyadenylation (PolyA) sequences, 6, 478, 480  
 Polyethylene glycol (PEG) polymer chain, 362  
 Polylactic acid–polyglycolic acid (PLGA)-based delivery systems, 84  
 Polysaccharide vaccines, 448  
 Polyvinyl chloride (PVC), 228  
 Posttransplant lymphoproliferative disorder (PTLD), 384  
 Prader-Willi syndrome (PWS), 293  
 PRCA. *See* Pure red cell aplasia (PRCA)  
 Preclinical safety assessment, MABs, 155–156  
 Progressive multifocal leukoencephalopathy (PML), 344, 402, 404, 407–408
- Protein contaminants and product variants  
 conformational changes/chemical modifications, 64  
 glycosylation, 64  
 “known”/expected contaminants, 64  
 N- and C-terminal heterogeneity, 64  
 proteolytic processing, 64–65  
 urokinase, 63
- Protein formulations  
 chemical and physical instability, 97  
 endocrine-, paracrine- and autocrine-acting proteins  
 dose-response relationship, 81  
 pathway, 81, 82  
 site-specific delivery and side effects, 81–82
- excipients  
 anti-adsorption agents, 70–71  
 anti-aggregation agents, 71  
 buffer components, 71, 72  
 osmotic agents, 72  
 preservatives and antioxidants, 71–72  
 solubility enhancers, 70, 71
- microbiology  
 pyrogen removal, 69–70  
 sterility, 69  
 viral decontamination, 69
- rate-controlled delivery (*see* Rate-controlled delivery, protein)  
 routes of administration (*see* Routes of administration, protein)

- shelf life (*see* Stability, protein)  
 site-specific delivery (*see* Drug-targeting process, protein)
- Proteolysis  
 by endopeptidases, 111  
 gastrointestinal tract, 107  
 glomerular filtration, 108  
 hepatic metabolism, 109  
 metabolic degradation, 107  
 molecular rate, 107, 108  
 proteases and peptidases, 107
- Proteomics  
 correlation, environmental factor, 192  
 description, 185  
 functional, 185  
 metabolomics, 188  
 pharmacogenomics, 189  
 proteins functions, 185  
 research, 185  
 structural, 185  
 technology platforms, 185
- PRRs. *See* Pattern recognition receptors (PRRs)
- Psoriasis  
 adalimumab, 405  
 alefacept, 402  
 anti-TNF biologic agents, 402  
 certolizumab pegol, 405  
 IBD, 403–404  
 infliximab, 405–406  
 natalizumab, 406  
 PASI, 401  
 psoralen plus ultraviolet A light therapy, 401  
 symptoms, 401  
 TNF $\alpha$  antagonists, 402–403  
 ustekinumab, 403
- PTLD. *See* Posttransplant lymphoproliferative disorder (PTLD)
- Public Health Service (PHS) Act, 250
- Pure red cell aplasia (PRCA), 369
- Purification, recombinant proteins  
 DSP, 13  
*E. coli*, 13  
 his-tagged proteins, 12, 13  
 methods, 12
- PVC. *See* Polyvinyl chloride (PVC)
- PWS. *See* Prader-Willi syndrome (PWS)
- Q**  
 QALY. *See* Quality-adjusted life-years (QALY)  
 Quality-adjusted life-years (QALY), 241, 243, 244  
 Quality-by-design approach, 251
- R**  
 Radioimmunotherapeutic (RIT) agents, 152–153  
 Radioimmunotherapy, 344–345  
 Rate-controlled delivery, protein  
 biosensor-pump combinations, 84–86  
 controlled release systems, 82, 83  
 covalent attachment, PEG, 82, 83  
 insulin, 82  
 microencapsulated secretory cells, 87–88  
 open-loop systems  
 biodegradable microspheres, 84, 85  
 mechanical pumps, 82–83  
 osmotically driven systems, 83–84  
 self-regulating systems, 86–87  
 RCA. *See* Replication-competent adenovirus (RCA)  
 Receptor activator of nuclear factor  $\kappa$  beta ligand (RANKL), 354–355  
 Recombinant coagulation factors  
 cascade model, 299, 300  
 cell-based model, 299, 300  
 endogenous regulatory mechanisms, 299  
 factor VIIA (*see* Recombinant factor VIIA)  
 factor VIII (*see* Recombinant factor VIII)  
 factor IX (*see* Recombinant factor IX)  
 factor XIII  
 multiple-dose study, 309  
 pharmacokinetics, 309  
*Saccharomyces cerevisiae*, 309  
 fibrinolytic pathway, 299, 300  
 hemophilia, 299–301  
 pegylation, 316  
 stroke and pulmonary embolism, 317  
 tissue factor (TF), 299  
 Recombinant factor IX-Fc fusion protein (rFIXFc), 309  
 Recombinant factor VIIA (rFVIIa)  
 anion-exchange chromatography, 304  
 baby hamster kidney cells, 304  
 cell-based concept, 303  
 Gla domain, 304  
 Glanzmann's thrombasthenia, 306  
 high titers, inhibitors, 303  
 in vitro characterization, 306  
 in vivo FVII depletion model, 306  
 NN1731, 306  
 NovoSeven<sup>®</sup>, 304  
 NovoSeven<sup>®</sup>RT, 306  
 pegylated liposomes, 307  
 pharmacokinetics and pharmacodynamics, 304–306  
 pharmacology, 304  
 purification, 304  
 rFVIIa, 304–307  
 safety, 306  
 structure, 303–304  
 tissue factor/activated platelets, 303  
 variants with sitedirected amino acid substitution, 306  
 Recombinant factor VIII (rFVIII)  
 administration, 301–302  
 Advate<sup>®</sup>, 301  
 antihemophilic factor, 301  
 Baxter, Bayer and Pfizer, 301, 302  
 biological potency, 301  
 dosage, 302–303  
 perioperative management in adults and children, 302  
 pharmacokinetics, 302, 303  
 pharmacology, 301  
 plasma protein, 301  
 rFVIII, 301–303  
 safety, 303  
 structure, 301  
 Recombinant factor IX  
 administration, 307–308  
 415 amino acid glycoprotein, 307  
 column chromatography steps, 307  
 dosage and duration, substitution treatment, 308  
 in vitro clotting assay, 307  
 in vivo recovery, 308  
 iso-osmolality, 307  
 N9-GP, 308–309  
 pharmacokinetics, 308  
 pharmacology, 307

- Recombinant factor IX (*cont.*)  
 plasma-derived factor IX carries, 307  
 recombinant, 307–309  
 rFIXFc, 309  
 room temperature storage, 307  
 safety, 308  
 thrombin, 307  
 transfected cell line secretes, 307
- Recombinant factor XIII  
 plasma transglutaminase and terminal enzyme, 309  
 recombinant, 309
- Recombinant FSH  
 ART program, 283  
 biochemical analysis, 282  
 corifollitropin alfa, 282–283  
 Elonva®, 283  
 female indications, 281  
 fewer injections, 282  
 follitropin- $\beta$ , 281  
 FTET cycles, 281  
 GnRH antagonists, 281  
 isohormones  
   biological properties, 280  
   pharmacokinetic behavior, 280  
 nonclinical evaluation, 282  
 O-linked glycosylation sites, 282  
 ovarian hyperstimulation syndrome, 281  
 pharmaceutical formulations  
   follitropin- $\alpha$  and  $\beta$ , 280  
   freeze-dried presentation form, 280–281  
   lyophilized preparations, 280  
   pen injectors, 281  
   Puregon®/Follistim® solution, 281  
 production, 279  
 structural characteristics, 279–280  
 treatment, anovulatory patients, 281
- Recombinant human DNase I (rhDNase I)  
 abnormal CFTR protein, 331–332  
 active site, enzyme, 324  
 anti-inflammatory properties, 331, 332  
 bovine pancreatic, 322–323  
 CFTR, 321  
 cystic fibrosis, 329–330  
 and cystic fibrosis, 321, 322  
 description, 321  
 DNA-rich secretions, 322  
 drug delivery, 328–329  
 enzymology, 323–324  
 extracellular DNA, 322  
 frequency, respiratory exacerbations, 331, 332  
 human pancreatic cDNA library, 323  
 hyperactive, 324  
 in vitro activity in CF sputum, 325–326  
 in vivo activity in CF sputum, 326–328  
 indication and clinical dosage, 329  
 inhibition, G-actin, 324  
 macromolecules, 322  
 nasal sinuses, 331  
 non-cystic fibrosis respiratory disease, 330–331  
 pharmacokinetics and metabolism, 326–328  
 primary amino acid sequence, 323  
 protein chemistry, 323  
 protein manufacturing and formulation, 328  
 pulmonary empyema, 331  
 reduction in viscoelasticity, 323  
 safety, 331  
 and SLE, 321  
*Staphylococcus aureus* and *Staphylococcus epidermidis*, 322  
 structure, 324  
 ultrasonic nebulizers generate heat, 331, 332  
 variants, 324
- Recombinant human erythropoietin (rHuEPO)  
 absorption, 364  
 bioavailability, 364  
 biosimilars manufacture, 362–363  
 clearance, 366  
 commercial form, 362  
 and darbepoetin alfa, 365  
 distribution, 365  
 dose, 367–368  
 molecules, 365  
 pharmacodynamics, 366–367  
 pharmacokinetic meta-analysis, 365–366  
 pharmacokinetic models, 366  
 serum rHuEPO levels, 368  
 trafficking and degradation, 365
- Recombinant peptide and protein vaccines, 450
- Recombinant proteins  
 biophysical and biochemical analysis (*see* Biophysical and biochemical analysis, recombinant proteins)  
 contaminants, purification process, 61–65  
 downstream processing, 54–61  
 manufacture, 65  
 upstream processing (*see* Upstream processing)
- Recombinant therapeutic proteins  
 cell culture, 12, 13  
 cloning PCR products  
   DNA sequencing, 11, 12  
   expression plasmid, mammalian cell line, 8, 10  
   TA cloning, 8, 9  
   transformation, 8  
 copyDNA  
   central dogma, molecular biology, 6, 7  
   messenger RNA synthesis, 5  
   and PCR, 8, 9  
   polyadenylation, 6  
   reverse-transcription, 5–6  
   RT, 6, 7  
   splicing, 5  
   thermostable DNA polymerase, 8, 9  
 DNA sequence, 4  
 expression host selection  
   bovine serum, 4  
   glycosylation, 5, 6  
   mammalian cells, 4, 5  
   PTM, 4  
 host cells transfection, 9–11  
 purification (*see* Purification, recombinant proteins)  
 selection, 4  
 steps, production, 3
- Recombinant thrombolytic agents  
 first-generation (*see* Recombinant t-PA (rt-PA))  
 second-generation, 313–316  
 t-PA, 309–311
- Recombinant t-PA (rt-PA)  
 acute ischemic stroke, 313  
 AMI management, 312  
 Cathflo Activase, 312  
 COBALT trial, 312  
 doses, 313

- GUSTO trial, 312
  - 3-h regimen, 312
  - patency grades, blood flow, 312
  - pharmacokinetics, 311
  - residue Asn184, 311
  - safety, 313
  - sterile lyophilized powder, 312
  - TIMI, 312
  - two dose regimens, 312
  - Regulatory framework, biosimilar products
    - analytical tools, 253–254
    - biopharmaceuticals, 247
    - cGMP, 248
    - CMC section, 247–248
    - complex proteins, 249
    - definitions, 247, 248
    - drug approval, generic product and biosimilar product (FDA), 247, 248
    - European Medicines Agency (EMA) (*see* EMA regulatory framework)
    - human growth hormone, 254
    - innovator's product characteristics and functional activity, 248
    - protein structures, 247
    - safety, innovator's drug product, 247
    - science-based regulatory policies, 254
    - small molecular weight drugs and macromolecular biopharmaceuticals, 247, 248
    - synthesized molecules, 254
    - in the USA (*see* USA regulatory framework)
  - Reimbursement, 232
  - REMS. *See* Risk evaluation and mitigation strategies (REMS)
  - Renal protein metabolism
    - elimination mechanism, 108
    - glomerular filtration, 108, 109
    - limitation, 108
    - pathways, 108, 109
    - peritubular extraction, 109
  - Replication-competent adenovirus (RCA), 486
  - Reteplase
    - administration, 313
    - AMI, 313
    - 355-amino deletion variant, t-PA, 313
    - GUSTO III trial, 314
    - and heparin, 313
    - INJECT trial, 313–314
    - pharmacology, 313, 314
    - potency, 313
    - RAPID 2, 314
    - safety, 314
    - second bolus injection, 313
    - sterile water for injection, USP, 313
    - stroke rate, 314
  - Retroviruses
    - biology, 482, 483
    - clinical use, 483–484
    - HEK293 cells, 482
    - limitation, 483
    - "stem-cell-based gene therapy", 482–483
  - Reverse transcriptase (RT), 6, 7
  - Reverse vaccinology, 451–452
  - rFIXFc. *See* Recombinant factor IX-Fc fusion protein (rFIXFc)
  - rhDNase I. *See* Recombinant human DNase I (rhDNase I)
  - Ribonucleoproteins, 463–464
  - Risk evaluation and mitigation strategies (REMS), 224
  - RIT agents. *See* Radioimmunotherapeutic (RIT) agents
  - Rituximab
    - antibody-mediated rejection, 385
    - B-cell lymphomas, 384
    - B cells, 385
    - CD20 antigen and protein, 384
    - chimeric murine/human IgG1 MAB, 384
    - description, 400
    - desensitization protocols, 385
    - desensitizing agent, 384
    - efficacy and safety, 400
    - FSGS, 385
    - plasmapheresis, 385
    - PTLD, 384
    - yttrium-90 (<sup>90</sup>Y) ibritumomab tiuxetan and iodine-131 (<sup>131</sup>I) tositumomab
      - CD20 antigen, 344
      - CHOP, 342–343
      - complete response rate (CR) plus, 342
      - conjunction with MAB, 344
      - pharmacology and pharmacokinetics, 342, 343
      - progression-free survival, 343
      - radioimmunotherapy, 344–345
      - safety, 344
      - safety profile, 343–344
      - single agent, 342
  - Romiplostim (Nplate®), 370–371
  - Routes of administration, protein
    - and absorption-enhancing effects
      - changes in glucose levels, 79
      - glycocholate and molecular weight, 79
      - intracutaneous delivery systems, 81
      - plasma profile, GRF, 80–81
      - reproducibility, 79
      - transdermal iontophoretic delivery, 80
    - alternative routes
      - approaches, bioavailability enhancement, 79
      - bioavailability, 78
      - nose, lungs, rectum, oral cavity and skin, 77–78
      - pulmonary insulin formulation, 78–79
    - oral route
      - bioavailability, 76
      - failure, uptake, 76
      - permeability, 77
      - Peyer's patches, 77
      - protein degradation in GI tract, 76–77
    - parenteral route
      - circulation half-life, t-PA, 75–76
      - definition, 75
      - differences in disposition, 76
      - prolonged residence time, 76
  - rt-PA. *See* Recombinant t-PA (rt-PA)
- S**
- SBS. *See* Short bowel syndrome (SBS)
  - Scale-up and postapproval changes (SUPAC)
    - "FDA guidance on comparability", 249, 254
    - manufacturing process, 249–250
    - proposed product, 249
    - in small molecules, 249
  - SCF. *See* Stem cell factor (SCF)
  - Self-regulating systems
    - approaches, 86

- Self-regulating systems (*cont.*)  
  competitive desorption approach, 86, 87  
  Con A-glycosylated insulin complex, 86, 87  
  drug release, 86  
  enzyme-substrate reactions, 87  
 $\beta$ -Sheet structure, proteins, 26  
Short bowel syndrome (SBS), 294  
Short stature homeobox-containing gene (SHOX), 293–294  
SHOX. *See* Short stature homeobox-containing gene (SHOX)  
Single-nucleotide polymorphisms (SNPs)  
  coding regions (cSNPs), 188  
  in CYP2D6 and CYP2C19, 191  
  databases, 189  
  DNA sequence variation, 188  
  and GWAS, 189  
  identification and mapping, 188–189  
  “snips”, 188  
  and type 2 diabetes, 189  
Sinusoidal obstructive syndrome (SOS), 342  
Site-directed mutagenesis, 208–209  
SLE. *See* Systemic lupus erythematosus (SLE)  
Small for gestational age (SGA), 293  
SNPs. *See* Single-nucleotide polymorphisms (SNPs)  
Solid organ transplantation  
  allograft rejection, 378  
  basiliximab (*see* Basiliximab)  
  calcineurin inhibitors, 378  
  cell-mediated immunity, 378  
  cellular-mediated rejection, 376  
  complications, current maintenance  
    immunosuppressants, 376, 377  
  daclizumab, 380  
  desensitization, 387, 388  
  distribution volume, 387, 388  
  host immune recognition, donor tissue, 375–376  
  host immune system recognizes donor tissue, 387, 388  
  IL-2 receptor antagonists, 379–380  
  induction immunosuppression, 376, 377  
  MHC, 387, 388  
  monoclonal antibody uses, 376  
  muromonab, 378–379  
  OKT3, 375  
  patient-specific factors, 375  
  per dose cost, 387  
  polyclonal antibodies, 375  
  posttransplant immunosuppression, 375  
  pre-transplant  
    blood samples, 377  
    desensitization, 377  
    immunologic barriers, 376  
    potential recipients, 377  
  signal transduction pathway, 376  
  time of transplant  
    cardiovascular events, 378  
    chronic administration, calcineurin inhibitors, 378  
    death in noncardiac transplant recipients, 377–378  
    patient and allograft adverse effects, 377  
    pharmacokinetic parameters, 378  
    plasma exchange procedures, 378  
    recipients, 378  
Solubility enhancers  
  aggregation, 70  
  approaches, 70  
  arginine effect, 70, 71  
Soluble carrier systems, targeted protein delivery  
  bispecific antibodies, 90  
  immunoconjugates, 90–91  
  MAB (*see* Monoclonal antibodies (MABs))  
Splicing, 5  
Squamous cell carcinoma of the head and neck (SCCHN), 352  
Stability, protein  
  compacted forms, 75  
  factors, 72  
  freeze-drying, 72–73  
  freezing  
    in amorphous systems, 74  
    crystallization, 73  
    “free and fluid” water, 74  
    thawing/cooling, 73, 74  
  pH dependence,  $\alpha_1$ -antitrypsin, 72  
  primary drying  
    DSC, 75  
    eutectic and glass transition temperature, 74  
    gas conduction, 74  
    parameters, 74  
    sublimation, 74  
  recombinant proteins, 33–34  
  secondary drying, 75  
  storage, 72  
Stem-cell-based gene therapy  
  description, 492  
  ESCs, 492  
  gene delivery vehicles, 493  
  MSCs, 492–493  
  regenerative medicine, 493–494  
Stem cell factor (SCF), 370  
Stem cell technology  
  adult stem cells (*see* Adult stem cells)  
  cancer stem cells, 520–521  
  cell therapy (*see* Cell therapy, stem cells)  
  definitions, cell potency, 509, 510  
  description, 521–522  
  direct reprogramming, 518  
  disease modeling and drug discovery, 519–520  
  ES cells (*see* Embryonic stem cells (ESCs))  
  IPS cell technology, 515–518  
  origin, characteristics and uses, 509, 510  
  regulatory issues, 521  
  significance, 509  
Storage  
  dosing and administration devices, 228–229  
  interferon- $\alpha_2$ , 226  
  in IV solutions, 229  
  light protection, 229  
  shelf-life, 226  
  temperature requirements, 226, 228  
Structural genomics  
  description, 181  
  and functional, 182  
  and HGP, 181  
  and proteomics, 185  
  variation, 182  
SUPAC. *See* Scale-up and postapproval changes (SUPAC)  
Synthetic biology, 209

Systemic lupus erythematosus (SLE), 394, 400–401  
 Systems biology  
   application, 199  
   characterization, 199  
   description, 199  
   information challenges, 184  
   SBGN, 199  
   and vaccines, 453  
 Systems Biology Graphical Notation (SBGN), 199

## T

Target-mediated drug disposition  
   description, 111  
   as elimination processes, 111  
   macrophage colony-stimulating factor (M-CSF), 111  
   multiple clearance pathways, 111, 112  
   trastuzumab, 111–112  
 T2DM patients, 264  
 Tenecteplase  
   administration, 315  
   ASSENT-2, 316  
   biological potency, 315  
   description, 315  
   intravenous bolus injection, 315  
   pharmacology, 315  
   reduction, mortality, 315  
   safety, 316  
   tetra-alanine substitution, 315  
   TIMI 10A and 10B, 315–316  
   T103N, 315  
   weight-adjusted dosing table, 315  
 Therapeutic proteins. *See also* Recombinant therapeutic proteins  
   PTM, 4  
   selection, 4  
 Thrombolysis in Myocardial Infarction (TIMI), 312  
 Thrombopoietin (TPO), 370  
 TIMI. *See* Thrombolysis in Myocardial Infarction (TIMI)  
 Tissue-type plasminogen activator (t-PA)  
   A- and B-chain, 311  
   and AMI, 309  
   asparagine 117, 309–310  
   complex N-linked glycan structures, 310  
   description, 309  
   fibrin and platelet depositions, 309  
   primary structure, 309, 310  
   serine protease synthesis, 309  
   single-chain t-PA polypeptide, 310–311  
   two-chain, 311  
   types, 309  
 Tocilizumab, 396, 400  
 Toxicogenomics  
   description, 196–197  
   genomic techniques, 197  
   manifestations, toxicity, 197  
   as new drug candidates, 197  
   systems models, 199  
 t-PA. *See* Tissue-type plasminogen activator (t-PA)  
 TPO. *See* Thrombopoietin (TPO)  
 Transcription regulatory elements (TRE), 478–479  
 Transcriptomics, 184–185

Transgenic animals  
   biopharmaceutical protein production  
     gene farming, 204  
     human proteins, list, 204, 205  
     protein purification, milk, 204, 205  
     yields, 206  
   cloned animals, 200  
   description, 200  
   foreign DNA sequences, 200  
   production by  
     DNA microinjection and gene addition, 200–202  
     pluripotent embryonic stem cell methodology, 202–204  
     retroviral infection, 202  
 Transgenic plants  
   agricultural enhancements, 204  
   cultured eukaryotic microalgae, 204  
   gene transfer technology, 204  
   human proteins, biopharmaceuticals list, 204, 205  
   pharming, 206  
 Trastuzumab  
   pharmacology and pharmacokinetics, 349, 350  
   safety, 350  
   treatment, Her-2-positive breast cancer, 349–350  
 TRE. *See* Transcription regulatory elements (TRE)  
 Triplex helix formation, oligonucleotides, 462–464  
 TS. *See* Turner syndrome (TS)  
 Tumor lysis syndrome (TLS), 344  
 Turner syndrome (TS), 293

## U

UFH. *See* Unfractionated heparin (UFH)  
 Unfractionated heparin (UFH), 242  
 Untranslated regions (UTR), 478, 480  
 Upstream processing  
   cultivation  
     medium, 53–54  
     systems, 49–53  
   expression systems, 47–49  
 USA regulatory framework  
   characterization, 251, 252  
   clinical studies, 251–252  
   drug product approval, 250  
   generic drug (small molecule), 249  
   guidance documents, 251  
   human pharmacokinetic and pharmacodynamic, 251  
   proposed product manufacturer, 251  
   protein product structure, 251  
   quality-by-design approach, 251  
   SUPAC, 249–250  
   “totality-of-the-evidence” approach, 251  
 Ustekinumab, 396, 402, 403  
 UTR. *See* Untranslated regions (UTR)

## V

Vaccines  
   categorization, 439, 440  
   characteristics, 439  
   classical, 446–448  
   description, 439  
   immunological principles, 440–446  
   modern (*see* Modern vaccine technologies)  
   pharmaceutical aspects, 453–455  
 Van der Waals interactions, 29

Vascular endothelial growth factor (VEGF) inhibitors  
  action mechanism, 347, 348  
  bevacizumab, 347–349  
  description, 347

Viral vectors, gene therapy  
  AAV, 487–488  
  adenoviruses, 484–487  
  characteristics, 481, 482  
  clinical trials, 481  
  construction and maintenance, 480–481  
  lentiviruses, 484  
  retroviruses, 482–484

**W**

Wasting syndromes, 294  
WCB. *See* Working cell bank (WCB)  
Working cell bank (WCB), 279

**X**

Xenotransplantation, 206

**Y**

Yttrium-90 (<sup>90</sup>Y) ibritumomab tiuxetan, 342–345